News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astex Pharmaceuticals (ASTX) Climbs on Expected European Approval



8/22/2012 8:42:50 AM

Astex Pharmaceuticals Inc. (ASTX) rose the most in almost seven months on expectations that the developer of experimental cancer drugs will receive regulatory approval this quarter from Europe for its leukemia treatment. Astex surged 15.4 percent to $2.77 at the close in New York, the most since Jan. 27. The shares of the Dublin, California-based company have risen 47 percent this year. “They’ve had a good run, really a great run since the middle of May,” George Zavoico, an analyst with McNicoll Lewis & Vlak LLC in New York, said in an interview. He has a buy rating on Astex, with a target price of $3.50.

Read at BusinessWeek
Read at Irish Times


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES